METFORMIN: an efficacy, safety and pharmacokinetic study on the short-term and long-term use in obese children and adolescents – study protocol of a randomized controlled study

Trials

Marja MJ van der Vorst¹  Catherijne AJ Knibbe³  Edgar GAH van Mil²  Marieke AJ Elst¹  Marloes P van der Aa¹ 

[1] Department of Paediatrics, St. Antonius Hospital, Koekoekslaan 1, 3435 CM Nieuwegein, The Netherlands;Department of Paediatrics, Jeroen Bosch Hospital, Henri Dunantstraat 1, 5223 GZ’s Hertogenbosch, The Netherlands;Department of Clinical Pharmacy, St. Antonius Hospital, Koekoekslaan 1, 3435 CM Nieuwegein, The Netherlands

关键词: Safety;    Pharmacokinetics;    Paediatric obesity;    Metformin;    Insulin resistance;    Efficacy;   

Others  :  805275
DOI  :  10.1186/1745-6215-15-207

 received in 2014-01-22, accepted in 2014-05-12,  发布年份 2014

【 摘 要 】

Background

The prevalence of childhood obesity and insulin resistance is rising, increasing the risk of diabetes mellitus type 2. To prevent these complications, lifestyle intervention is the corner stone in treatment. However, long-term efficacy of lifestyle intervention is questionable. In addition to lifestyle intervention, pharmacological treatments have been explored. Metformin has been shown to be moderately effective to reduce BMI in obese adolescents with hyperinsulinemia. However, data on pharmacokinetics and long-term efficacy and safety are lacking as well as an evidence-based dosing regimen for this age group. The primary objective of the METFORMIN study is to determine the effect of adding metformin treatment to lifestyle intervention in reducing BMI in obese adolescents with insulin resistance. In addition, the pharmacokinetics of metformin in obese adolescents will be studied.

Methods/design

The METFORMIN study is a multi-centre prospective study that consists of two 18-month phases: a double-blind randomized placebo-controlled trial (part 1) and an open-label follow-up study (part 2). During part 1, the participants will be given metformin 1,000 mg or placebo twice daily and will be offered a lifestyle intervention programme; 144 participants will be included, 72 in each arm. Primary endpoints are reduction in body mass index, insulin resistance, and percentage body fat.

Discussion

This study will provide data on short- and long-term efficacy and safety of metformin and on the pharmacokinetics of metformin in obese adolescents.

Trial registration

ClinicalTrials.gov numberNCT01487993; EudraCT nr. 2010-023980-17. Registration date: 06-01-2011

【 授权许可】

   
2014 van der Aa et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Lobstein T, Baur L, Uauy R: Obesity in children and young people: a crisis in public health. Obes Rev 2004, 5(1):4-104.
• [2]Lobstein T, Frelut ML: Prevalence of overweight among children in Europe. Obes Rev 2003, 4:195-200.
• [3]TNO: Factsheet Resultaten Vijfde Landelijke Groeistudie TNO. 2010. [ https://www.tno.nl/downloads/20100608%20Factsheet%20Resultaten%20Vijfde%20Landelijke%20Groeistudie1.pdf webcite]
• [4]Freedman DS, Dietz WH, Srinivasan SR, Berenson GS: The relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa Heart Study. Pediatrics 1999, 103:1175-1182.
• [5]Reilly JJ, Methven E, McDowell ZC, Hacking B, Alexander D, Stewart L, Kelnar CJ: Health consequences of obesity. Arch Dis Child 2003, 88:748-752.
• [6]Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, Allen K, Lopes M, Savoye M, Morrison J, Sherwin RS, Caprio S: Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004, 350:2362-2374.
• [7]Dietz WH: Childhood weight affects adult morbidity and mortality. J Nutr 1998, 128:411S-414S.
• [8]Ebbeling CB, Pawlak DB, Ludwig DS: Childhood obesity: public-health crisis, common sense cure. Lancet 2002, 360:473-482.
• [9]Whitaker RC, Wright JA, Pepe MS, Seidel KD, Dietz WH: Predicting obesity in young adulthood from childhood and parental obesity. N Engl J Med 1997, 337:869-873.
• [10]McGovern L, Johnson JN, Paulo R, Hettinger A, Singhal V, Kamath C, Erwin PJ, Montori VM: Clinical review: treatment of pediatric obesity: a systematic review and meta-analysis of randomized trials. J Clin Endocrinol Metab 2008, 93:4600-4605.
• [11]Oude Luttikhuis H, Baur L, Jansen H, Shrewsbury VA, O'Malley C, Stolk RP, Summerbell CD: Interventions for treating obesity in children. Cochrane Database Syst Rev 2009., 1CD001872
• [12]Park MH, Kinra S, Ward KJ, White B, Viner RM: Metformin for obesity in children and adolescents: a systematic review. Diabetes Care 2009, 32:1743-1745.
• [13]Kamath CC, Vickers KS, Ehrlich A, McGovern L, Johnson J, Singhal V, Paulo R, Hettinger A, Erwin PJ, Montori VM: Clinical review: behavioral interventions to prevent childhood obesity: a systematic review and meta-analyses of randomized trials. J Clin Endocrinol Metab 2008, 93:4606-4615.
• [14]Van Mil EG, Westerterp KR, Kester AD, De Waal HAD, Gerver WJ, Saris WH: The effect of sibutramine on energy expenditure and body composition in obese adolescents. J Clin Endocrinol Metab 2007, 92:1409-1414.
• [15]Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J: Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005, 293:2873-2883.
• [16]Maahs D, De Serna DG, Kolotkin RL, Ralston S, Sandate J, Qualls C, Schade DS: Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract 2006, 12:18-28.
• [17]UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with Metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865.
• [18]Golay A: Metformin and body weight. Int J Obes (Lond) 2008, 32:61-72.
• [19]Atabek ME, Pirgon O: Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial. J Pediatr Endocrinol Metab 2008, 21:339-348.
• [20]Burgert TS, Duran EJ, Goldberg-Gell R, Dziura J, Yeckel CW, Katz S, Tamborlane WV, Caprio S: Short-term metabolic and cardiovascular effects of Metformin in markedly obese adolescents with normal glucose tolerance. Pediatr Diabetes 2008, 9:567-576.
• [21]Freemark M: Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatr 2007, 96:1326-1332.
• [22]Harden KA, Cowan PA, Velasquez-Mieyer P, Patton SB: Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents. J Am Acad Nurse Pract 2007, 19:368-377.
• [23]Kay JP, Alemzadeh R, Langley G, D’Angelo L, Smith P, Holshouser S: Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001, 50:1457-1461.
• [24]Love-Osborne K, Sheeder J, Zeitler P: Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. J Pediatr 2008, 152:817-822.
• [25]Srinivasan S, Ambler GR, Baur LA, Garnett SP, Tepsa M, Yap F, Ward GM, Cowell CT: Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab 2006, 91:2074-2080.
• [26]Uli N, Sundararajan S, Cuttler L: Treatment of childhood obesity. Curr Opin Endocrinol Diabetes Obes 2008, 15:37-47.
• [27]Metformin: new indication: Useful for some children with type 2 diabetes. Prescrire Int 2007, 16:50-52.
• [28]Jones KL: Why test the children? Understanding insulin resistance, its complications, and its progression. Diabetes Care 2002, 25:2350-2351.
• [29]Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ: Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2002, 25:89-94.
• [30]Peterson K, Silverstein J, Kaufman F, Warren-Boulton E: Management of type 2 diabetes in youth: an update. Am Fam Physician 2007, 76:658-664.
• [31]Zeitler P, Epstein L, Grey M, Hirst K, Kaufman F, Tamborlane W, Wilfley D: Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of Metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes 2007, 8:74-87.
• [32]Knibbe CA, Krekels EH, Danhof M: Advances in paediatric pharmacokinetics. Expert Opin Drug Metab Toxicol 2011, 7:1-8.
• [33]De Cock RF, Piana C, Danhof M, Allegaert K, Knibbe CA: The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol 2011, 67(Suppl 1):5-16.
• [34]Knibbe CA, Danhof M: Individualized dosing regimens in children based on population PKPD modelling: Are we ready for it? Int J Pharm 2011, 415(1–2):9-14.
• [35]Becker ML, Visser LE, Van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH: Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of Metformin in patients with diabetes: a preliminary study. Diabetes 2009, 58:745-749.
• [36]Becker ML, Visser LE, Van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH: Genetic variation in the organic cation transporter 1 is associated with Metformin response in patients with diabetes mellitus. Pharmacogenomics J 2009, 9:242-247.
• [37]Becker ML, Visser LE, Van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH: Interaction between polymorphisms in the OCT1 and MATE1 transporter and Metformin response. Pharmacogenet Genomics 2010, 20:38-44.
• [38]Kolotkin RL, Zeller M, Modi AC, Samsa GP, Quinlan NP, Yanovski JA, Bell SK, Maahs DM, de Serna DG, Roehrig HR: Assessing weight-related quality of life in adolescents. Obesity 2006, 14:448-457.
• [39]Wouters EJM, Geenen R, Kolotkin RL, Vingerhoets AJJM: Met lichaamsgewicht samenhangende kwaliteit van leven bij adolescenten (2010). Psychometrische kwaliteit van de Nederlandse vertaling van de IWQOL-Kids. Tijdschrift voor Kindergeneeskunde 2010, 78:119-125.